Screener
McKesson MCK North American Pharmaceutical — Total reserve balance
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:RestructuringReserve.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | North American Pharmaceutical | Prescription Technology Solutions | Medical-Surgical Solutions | Corporate | Total |
|---|---|---|---|---|---|
| Balance, March 31, 2026 (1) | $18 | $3 | $10 | $13 | $44 |
| Restructuring, impairment, and related charges, net | 2 | 61 | 23 | 50 | 136 |
| Non-cash charges | (1) | (40) | — | (6) | (47) |
| Cash payments | (3) | — | (16) | (40) | (59) |
| Balance, June 30, 2026 (2) | $16 | $24 | $17 | $17 | $74 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's north american pharmaceutical — total reserve balance?
- McKesson (MCK) reported north american pharmaceutical — total reserve balance of $16M in Q2 2026.
- What does north american pharmaceutical — total reserve balance mean?
- This metric represents the cumulative liability balance set aside for specific restructuring or contingency programs within the North American Pharmaceutical segment. It tracks the remaining funds earmarked for future payments related to previously announced organizational changes.
Ask your AI about McKesson's north american pharmaceutical — total reserve balance.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude